Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN-? ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN-?. Additionally, CTL with lytic activity do not always secrete IFN-? (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
From the reviews of the first edition:
"This book represents the first comprehensive description, and evaluation of the most important assays utilized to monitor immune responses against tumor associated antigens. ... Specifically tailored to the needs of clinical researchers, basic science investigators, and biotechnology innovators, this book provides information that is both sufficiently detailed and eloquently succinct. All discussions are substantiated with a comprehensive literature review. ... Analyzing T Cell Responses provides the most substantial and extensive review of immune response-monitoring techniques available to date." (Melanie Hayden, Stephanie Schroter and Boris Minev, Angiogenesis, Vol. 9, 2006)
Chapter 1: Monitoring Antigen-Specific T Cell Responses; Dirk Nagorsen, Francesco M. Marincola
Chapter 2: Tumor Associated Antigens; Paul F. Robbins
Chapter 3: Immune Escape, Tumor induced immune suppression and immune escape: Mechanisms and Possible Solutions; Theresa L. Whiteside, Michael Campoli, Soldano Ferrone
Chapter 4: Virus Specific T-Cell Responses; Victor Appay
Chapter 5: Cytotoxicity Assays Killer Lymphocytes in Cancer; Gideon Berke & William R. Clark
Chapter 6: Monitoring T Cell Proliferation; Philip D. Hodgkin, Edwin D. Hawkins, Jhaguaral Hasbold, Amanda V. Gett, Elissa K. Deenick, Hilary F. Todd & Mirja Hommel
Chapter 7: Elispot Assay, Assessment of Cellular Immune Responses to Anti-Cancer Vaccines; Theresa L. Whiteside
Chapter 8: Modified Elispot, Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials; Anatoli Malyguine
Chapter 9: Intracellular Cytokine Staining, Cytokine flow cytometry for characterization of tumor-specific T cell responses; Carmen Scheibenbogen, Anne Letsch, Anne Marie Asemissen, Alexander Schmittel, Eckhard Thiel & Ulrich Keilholz
Chapter 10: Cytometric Cytokine Secretion Assay, Detection and Isolation of Antigen-Specific T Cells; Mario Assenmacher
Chapter 11: Peptide/MHC Tetramer Analysis; Peter P. Lee & Francesco M. Marincola
Chapter 12: In Situ MHC Tetramer Staining, In Situ Tetramers; Pamela J. Skinner
Chapter 13: MHC-IG Dimeric Molecules, Dimers - MHC-Ig dimeric molecules for the analysis of antigen-specific T cell responses; Tim F. Greten & Firouzeh Korangy
Chapter 14: TCR Analyses, T-cell receptor CDR3 analysis: Molecular fingerprinting of the T-cell receptor repertoire; Markus J. Maeurer
Chapter 15: Peptide/HLA-GFP Complexes, Detection of Antigen-Specific T Cells by Acquisition of Peptide/Hla-Gfp Complexes; Utano Tomaru, Yoshihisa Yamano & Steven Jacobson
Chapter 16: QRT-PCR, Quantitative RT-PCR for the Analysis of T cell Responses in Immunized Cancer Patients; Udai S. Kammula
Chapter 17: Microarrays, Gene expression profiling approaches for the monitoring of anti-cancer immune responses; Ena Wang
Concluding Remarks; Dirk Nagorsen & Francesco M. Marincola
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
EUR 22,90 per la spedizione da Regno Unito a U.S.A.
Destinazione, tempi e costiGRATIS per la spedizione in U.S.A.
Destinazione, tempi e costiDa: The Book Exchange, Macclesfield, CHESH, Regno Unito
Hardcover. Condizione: Near Fine. 1402036221. Hardcover, from closed pharmaceutical company library. Lending record shows this book has never been borrowed. 313 pages, index, illustrated with charts, tables and diagrams. A critical assessment of all assays that have been used for the monitoring of antigen-specific immune responses. Emphasizes a global approach to the analysis of T cell mediated target/host interactions at the systemic and the peripheral level when such interactions are supposed to occur. Useful in the search of surrogate biomarkers predictive of treatment responsiveness and/or clinical outcome that are of interest to the biotechnology industry. Provides an overview of antigen-specific immune biology in human models of tumor and viral disease, discusses modulation of such responses through immune escape and presents cellular assays (cytoxicity, proliferation, cytokine production using ELISPOT, intracellular staining or cytometric assessment, detection of antigen-specific T cells with tetrameric HLA/epitope complexes or MHC-IG dimers, T cell receptor analysis, assessment of T cell receptor/HLA interactions using peptide/HLA-Green Fluorescent Protein complexes incorporation) and molecular assays including quantitative real-time PCR and gene profiling for evaluation of systemic and peripheral immune responses. Contents clean, tight and bright. Book. Codice articolo 031948
Quantità: 1 disponibili
Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Codice articolo ABNR-82553
Quantità: 1 disponibili
Da: Basi6 International, Irving, TX, U.S.A.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Codice articolo ABEOCT25-153898
Quantità: 1 disponibili
Da: ALLBOOKS1, Direk, SA, Australia
Brand new book. Fast ship. Please provide full street address as we are not able to ship to P O box address. Codice articolo SHAK153898
Quantità: 1 disponibili
Da: Lucky's Textbooks, Dallas, TX, U.S.A.
Condizione: New. Codice articolo ABLIING23Mar2411530142909
Quantità: Più di 20 disponibili
Da: Ria Christie Collections, Uxbridge, Regno Unito
Condizione: New. In. Codice articolo ria9781402036224_new
Quantità: Più di 20 disponibili
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell. 328 pp. Englisch. Codice articolo 9781402036224
Quantità: 2 disponibili
Da: preigu, Osnabrück, Germania
Buch. Condizione: Neu. Analyzing T Cell Responses | How to analyze cellular immune responses against tumor associated antigens | Dirk Nagorsen (u. a.) | Buch | xii | Englisch | 2005 | Springer | EAN 9781402036224 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand. Codice articolo 102229227
Quantità: 5 disponibili
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
Buch. Condizione: Neu. Neuware -Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 328 pp. Englisch. Codice articolo 9781402036224
Quantità: 2 disponibili
Da: AHA-BUCH GmbH, Einbeck, Germania
Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials (1-3). To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined, since it would facilitate the rapid comparison of these various formulations. Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are not quantitative. In contrast, novel assays such as enzyme-linked immunospot (ELISPOT) assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay has the 5 lowest detection limit with 1/10 peripheral blood mononuclear cells (PBMC) and has been determined to be one of the most useful assays to evaluate immune response to cancer vaccines (4). However, the IFN- ELISPOT assay is not an exclusive measure of cytotoxic T-lymphocyte (CTL) activity as non-cytotoxic cells can also secrete IFN- . Additionally, CTL with lytic activity do not always secrete IFN- (5). A more relevant approach to assess functional activity of cytotoxic lymphocytes would be to measure the secretion of molecules that are associated with lytic activity. One of the major mechanisms of cell-mediated cytotoxicity involves exocytosis of cytoplasmic granules from the effector toward the target cell. Codice articolo 9781402036224
Quantità: 1 disponibili